Bispecific T cell engager (BiTE®) antibody constructs can mediate bystander tumor cell killing
Year: 2017
Type: article
Abstract: For targets that are homogenously expressed, such as CD19 on cells of the B lymphocyte lineage, immunotherapies can be highly effective. Targeting CD19 with blinatumomab, a CD19/CD3 bispecific antibody construct (BiTE®), or with chimeric antigen receptor T cells (CAR-T) has shown great promise for treating certain CD19-positive hematological malignancies. In contrast, solid tumors with heterogeneous expression of the tumor-associated antigen (TAA) may present a challenge for targeted therapies. To prevent escape of TAA-negative cancer cells, immunotherapies with a local bystander effect would be beneficial. As a model to investigate BiTE®-mediated bystander killing in the solid tumor setting, we used epidermal growth factor receptor (EGFR) as a target. We measured lysis of EGFR-negative populations in vitro and in vivo when co-cultured with EGFR-positive cells, human T cells and an EGFR/CD3 BiTE® antibody construct. Bystander EGFR-negative cells were efficiently lysed by BiTE®-activated T cells only when proximal to EGFR-positive cells. Our mechanistic analysis suggests that cytokines released by BiTE®-activated T-cells induced upregulation of ICAM-1 and FAS on EGFR-negative bystander cells, contributing to T cell-induced bystander cell lysis.
Source: PLoS ONE
Authors: Sandra L. Ross(Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Writing – original draft, Writing – review & editing), Marika Sherman(Investigation, Methodology, Visualization, Writing – review & editing), Patricia L. McElroy(Investigation, Methodology, Writing – review & editing), Julie A. Lofgren(Investigation, Methodology, Writing – review & editing), Gordon Moody(Conceptualization, Methodology, Supervision, Writing – review & editing), Patrick A. Baeuerle(Formal analysis, Writing – original draft, Writing – review & editing), Angela Coxon(Supervision, Writing – review & editing), Tara Arvedson(Conceptualization, Formal analysis, Methodology, Supervision, Writing – original draft, Writing – review & editing)
Institutions: Amgen (United States), Amgen (Germany)
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $2,382
Funder: Amgen
OpenAlex ID: W2747396160
